Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2008 Dec;9(17):3083-94. doi: 10.1517/14656560802489569 .

Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

Author information

  • 1University of Miami Miller School of Medicine, 1200 NW 195TH Street, Suite 857, Miami, FL 33136, USA. dajayawee@med.miami.edu

Abstract

BACKGROUND:

Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations.

OBJECTIVE:

To understand the unique features of etravirine and to evaluate its safety, efficacy, and optimal use.

METHODS:

The structure and the mechanism of action of etravirine in blocking the reverse transcriptase enzyme and the preclinical, pharmacokinetic and pharmacodynamic studies were reviewed. The DUET Phase III clinical trials and the resistance profile of etravirine were evaluated.

CONCLUSIONS:

Etravirine has unique activity against most HIV isolates that are resistant to other NNRTIs. Unlike other NNRTIs, it has a higher genetic barrier to developing high-grade resistance. In the DUET studies, etravirine demonstrated virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are important drug interactions that will need to be taken into consideration with its use.

PMID:
19006480
DOI:
10.1517/14656560802489569
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center